| Management target | Revenue 20.0% FY27 |
|---|
| Revenue growth | 20% YoY guidance for FY27. |
|---|---|
| Margins | MedTech EBITDA at 20% vs Renewables at 11%. |
| Order book | 3000 Cr in LED/Renewables; 500+ dialysis machines. |
| Demand visibility | Strong via 3000 Cr order book and National Sickle Cell Mission. |
| Management confidence | High; cited 'monopolistic' technologies and strong government partnerships. |
Growth
Topline reached 280 Cr with 32 Cr PAT. Management expects H2 to outperform H1 due to seasonal B2G cycles.
Outlook
Guided for 1550 Cr revenue in FY27. Long-term target of 2000 Cr+ by FY28 with 10-11% PAT margins.
Risks
Regulatory delays for ICMR/CDSCO approvals on new MedTech products and high promoter shareholding requiring dilution.
Earnings Call Transcript filed with BSE, NSE: KRATOSENER. Summary written with AI assistance from the document.
Lords Mark Industries Ltd: key numbers
- Share price
- ₹92.77
- Market cap
- ₹3,958 Cr
- Revenue (annual)
- ₹684.8 Cr
- Net profit (annual)
- ₹48.59 Cr
- P/E (TTM)
- 47.4×Sector 22.0×
- Promoter holding
- 79.84%-1.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lords Mark Industries Ltd
All →Lords Mark Industries Business Update
Promoter Sachidanand Hariram Upadhyay proposed reinvesting proceeds from his prior sale of shares into the company's medical device unit expansion.
- Value
- ₹87.38 Cr
Lords Mark Industries Business Update
Lord’s Mark Industries has advanced its AI-powered breast cancer screening technology to final clinical trial stages. The company targets a global commercial launch by April 2027.
Lords Mark Industries Promoter Selling: ₹87.39 Cr
Promoter Director Mr. Sachidanand H Upadhyay sold 1.04 crore shares on BSE for ₹87.39 Crore. Stake reduced from 77.54% to 75.11%.
- Value
- ₹87.39 Cr
Lords Mark Industries Promoter Selling
Lord's Mark promoter Sachidanand Upadhyay disposed 1.04 crore shares via open market, cutting his stake from 77.54% to 75.11%.
Lords Mark Industries Capacity Expansion
Lord's Mark Industries completed Phase I Silvassa expansion, adding 18 surgical/orthopaedic SKUs (36 to 54). Commercial operations commence October 11, 2026.
- surgical and orthopaedic product SKUs
- 54 SKUs
Lords Mark Industries Investor Presentation: Key Takeaways
Lord's Mark Industries is a MedTech and Renewable Energy conglomerate focused on high-margin diagnostic innovations and a ₹3,000+ Cr solar order pipeline.